MX2013014461A - Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas. - Google Patents
Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.Info
- Publication number
- MX2013014461A MX2013014461A MX2013014461A MX2013014461A MX2013014461A MX 2013014461 A MX2013014461 A MX 2013014461A MX 2013014461 A MX2013014461 A MX 2013014461A MX 2013014461 A MX2013014461 A MX 2013014461A MX 2013014461 A MX2013014461 A MX 2013014461A
- Authority
- MX
- Mexico
- Prior art keywords
- sustained release
- release formulations
- eye
- delivery
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona formulaciones de liberación sostenida farmacéuticas inyectables para el suministro de agentes activos, particularmente proteínas terapéuticas, al ojo. Las formulaciones son formulaciones de liberación sostenida, biocompatibles, biodegradables que comprenden excipientes líquidos de baja solubilidad y cantidades relativamente pequeñas (menos de aproximadamente 10%) de polímero biocompatible, biodegradable tales como polímeros de PLA o PLGA. Una dosis unitaria de 5 µL a 100 µL de la formulación proporciona liberación sostenida del agente durante por lo menos 14 días.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161495672P | 2011-06-10 | 2011-06-10 | |
PCT/US2012/041950 WO2013036309A2 (en) | 2011-06-10 | 2012-06-11 | Sustained release formulations for delivery of proteins to the eye and methods of preparing same |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014461A true MX2013014461A (es) | 2014-05-14 |
MX359119B MX359119B (es) | 2018-09-14 |
Family
ID=47832748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014461A MX359119B (es) | 2011-06-10 | 2012-06-11 | Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas. |
Country Status (21)
Country | Link |
---|---|
US (1) | US9814773B2 (es) |
EP (1) | EP2717914B1 (es) |
JP (1) | JP6339011B2 (es) |
KR (1) | KR20140060274A (es) |
CN (1) | CN103945865B (es) |
AU (1) | AU2012304909B2 (es) |
BR (1) | BR112013031685B1 (es) |
CA (1) | CA2838289C (es) |
CY (1) | CY1122771T1 (es) |
DK (1) | DK2717914T3 (es) |
ES (1) | ES2761340T3 (es) |
HR (1) | HRP20192276T1 (es) |
HU (1) | HUE047737T2 (es) |
IN (1) | IN2013MN02384A (es) |
LT (1) | LT2717914T (es) |
MX (1) | MX359119B (es) |
PL (1) | PL2717914T3 (es) |
PT (1) | PT2717914T (es) |
RS (1) | RS60051B1 (es) |
SI (1) | SI2717914T1 (es) |
WO (1) | WO2013036309A2 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014190248A1 (en) * | 2013-05-24 | 2014-11-27 | Icon Bioscience, Inc. | Use of sustained release dexamethasone in post-cataract surgery inflammation |
AU2015257651B2 (en) * | 2014-05-08 | 2020-01-23 | Panoptes Pharma Ges.M.B.H. | Compounds for treating ophthalmic diseases and disorders |
ES2969514T3 (es) * | 2015-03-18 | 2024-05-21 | Santen Pharmaceutical Co Ltd | Composición farmacéutica de liberación sostenida |
US20180185489A1 (en) * | 2015-07-01 | 2018-07-05 | Santen Pharmaceutical Co., Ltd. | Depot preparation containing citric acid ester |
WO2017024027A1 (en) * | 2015-08-03 | 2017-02-09 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
FI3352735T3 (fi) | 2015-09-21 | 2023-10-20 | Teva Pharmaceuticals Int Gmbh | Pitkitetysti vapauttavia olantsapiiniformulaatioita |
JP2020511483A (ja) | 2017-03-20 | 2020-04-16 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | 徐放性オランザピン製剤 |
KR101957599B1 (ko) | 2017-10-23 | 2019-03-13 | 김상현 | 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지 |
WO2019157198A2 (en) | 2018-02-09 | 2019-08-15 | Icon Bioscience, Inc. | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
JP2021523223A (ja) | 2018-05-01 | 2021-09-02 | チビ,インコーポレイティド | 眼への薬物の非侵襲的な持続型送達のための液体デポー |
MX2020011535A (es) | 2018-05-01 | 2020-11-24 | Chibi Inc | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. |
US11439685B2 (en) | 2020-05-22 | 2022-09-13 | Trustees Of Boston University | Formulations for treating a fibrotic disease |
EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2658432B1 (fr) * | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
JP2004511431A (ja) * | 2000-06-28 | 2004-04-15 | アトゥル・ジェイ・シュクラ | 生物活性物質を含む生分解性ビヒクルおよび送達システム |
AR039729A1 (es) * | 2002-06-25 | 2005-03-09 | Alza Corp | Formulaciones de deposito de corta duracion |
US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
WO2004108111A1 (en) * | 2003-05-30 | 2004-12-16 | Alza Corporation | Implantable elastomeric depot compositions, uses thereof and method of manufacturing |
US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
MX344532B (es) * | 2004-10-01 | 2016-12-19 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
KR20070083941A (ko) * | 2004-10-04 | 2007-08-24 | 큐엘티 유에스에이, 인코포레이티드 | 중합체 전달 조성을 갖는 눈 전달 |
US8039010B2 (en) * | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
WO2010105093A2 (en) * | 2009-03-12 | 2010-09-16 | Delpor, Inc. | Implantable device for long-term delivery of drugs |
ES2672806T3 (es) * | 2009-07-03 | 2018-06-18 | Armbruster Biotechnology Gmbh | Injerto óseo y material biocompuesto |
-
2012
- 2012-06-11 JP JP2014514933A patent/JP6339011B2/ja active Active
- 2012-06-11 IN IN2384MUN2013 patent/IN2013MN02384A/en unknown
- 2012-06-11 ES ES12829655T patent/ES2761340T3/es active Active
- 2012-06-11 BR BR112013031685-3A patent/BR112013031685B1/pt active IP Right Grant
- 2012-06-11 LT LTEP12829655.5T patent/LT2717914T/lt unknown
- 2012-06-11 DK DK12829655.5T patent/DK2717914T3/da active
- 2012-06-11 KR KR1020147000443A patent/KR20140060274A/ko not_active Application Discontinuation
- 2012-06-11 CA CA2838289A patent/CA2838289C/en active Active
- 2012-06-11 US US14/124,631 patent/US9814773B2/en active Active
- 2012-06-11 PT PT128296555T patent/PT2717914T/pt unknown
- 2012-06-11 MX MX2013014461A patent/MX359119B/es active IP Right Grant
- 2012-06-11 RS RS20191574A patent/RS60051B1/sr unknown
- 2012-06-11 HU HUE12829655A patent/HUE047737T2/hu unknown
- 2012-06-11 EP EP12829655.5A patent/EP2717914B1/en active Active
- 2012-06-11 PL PL12829655T patent/PL2717914T3/pl unknown
- 2012-06-11 SI SI201231706T patent/SI2717914T1/sl unknown
- 2012-06-11 WO PCT/US2012/041950 patent/WO2013036309A2/en active Application Filing
- 2012-06-11 CN CN201280028816.4A patent/CN103945865B/zh active Active
- 2012-06-11 AU AU2012304909A patent/AU2012304909B2/en active Active
-
2019
- 2019-12-17 HR HRP20192276TT patent/HRP20192276T1/hr unknown
-
2020
- 2020-01-17 CY CY20201100042T patent/CY1122771T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
RS60051B1 (sr) | 2020-04-30 |
BR112013031685A2 (pt) | 2017-02-07 |
HRP20192276T1 (hr) | 2020-05-15 |
HUE047737T2 (hu) | 2020-05-28 |
MX359119B (es) | 2018-09-14 |
NZ619707A (en) | 2015-01-30 |
CY1122771T1 (el) | 2021-05-05 |
CN103945865B (zh) | 2016-10-26 |
EP2717914B1 (en) | 2019-10-30 |
LT2717914T (lt) | 2020-03-25 |
AU2012304909A1 (en) | 2013-12-19 |
US20140140992A1 (en) | 2014-05-22 |
CA2838289A1 (en) | 2013-03-14 |
AU2012304909B2 (en) | 2017-06-08 |
BR112013031685B1 (pt) | 2021-04-06 |
US9814773B2 (en) | 2017-11-14 |
JP2014516087A (ja) | 2014-07-07 |
ES2761340T3 (es) | 2020-05-19 |
KR20140060274A (ko) | 2014-05-19 |
CA2838289C (en) | 2019-09-10 |
JP6339011B2 (ja) | 2018-06-06 |
SI2717914T1 (sl) | 2020-07-31 |
EP2717914A4 (en) | 2015-05-13 |
CN103945865A (zh) | 2014-07-23 |
WO2013036309A2 (en) | 2013-03-14 |
DK2717914T3 (da) | 2020-01-20 |
IN2013MN02384A (es) | 2015-06-12 |
WO2013036309A3 (en) | 2013-05-10 |
PL2717914T3 (pl) | 2020-05-18 |
EP2717914A2 (en) | 2014-04-16 |
PT2717914T (pt) | 2019-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013014461A (es) | Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas. | |
WO2016042163A3 (en) | Ophthalmic drug compositions | |
NZ704011A (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
IN2013DN02524A (es) | ||
WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
WO2012054500A3 (en) | Compositions for drug administration | |
MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
MX2015011393A (es) | Poli(beta-amino esteres) modificados para suministro de farmaco. | |
SG194175A1 (en) | Polymer conjugated prostaglandin analogues | |
UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
MX366230B (es) | Composiciones multipolimericas para liberación transdermica de farmaco. | |
WO2011112996A3 (en) | Injectable drug delivery system | |
MX2018001499A (es) | Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. | |
MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
NZ700182A (en) | Parenteral formulations for administering macrolide antibiotics | |
MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
WO2014104974A3 (en) | Self-assembling ultrashort peptides modified with bioactive agents by click chemistry | |
PH12014502366A1 (en) | Injectable formulation | |
MX2022003939A (es) | Composicion farmaceutica de estabilidad mejorada. | |
WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
MX2012013872A (es) | Formas de dosificacion oral de bendamustina. | |
MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
BR112015011294A8 (pt) | nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas | |
EA201890703A1 (ru) | Коллоидные частицы, предназначенные для применения в медицине |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |